AML1-ETO fusion gene is generated from chromosomal translocation t(8;21) mainly in acute myeloid leukemia M2 subtype (AML-M2). Its spliced variant transcript, AML1-ETO9a, rapidly induces leukemia in murine model. To evaluate its clinical significance, AML1-ETO9a expression was assessed in 118 patients with t(8;21) AML-M2, using qualitative and nested quantitative reverse transcriptase (RT)-PCR methods. These cases were accordingly divided into the AML1-ETO9a-H group (n ¼ 86, positive for qualitative RT-PCR, with higher level of AML1-ETO9a by quantitative RT-PCR) and the AML1-ETO9a-L group (n ¼ 32, negative for qualitative RT-PCR, with lower but still detectable level of AML1-ETO9a by quantitative RT-PCR). C-KIT expression was significantly increased in the AML1-ETO9a-H group, as compared with the AML1-ETO9a-L group. Of the 36 patients harboring C-KIT mutations, 32 patients overexpressed AML1-ETO9a (P ¼ 0.0209). Clinically, AML1-ETO9a-H patients exhibited significantly elevated white blood cells count, less bone marrow aberrant myelocytes, increased CD56 but decreased CD19 expression (P ¼ 0.0451, P ¼ 0.0479, P ¼ 0.0149 and P ¼ 0.0298, respectively). Moreover, AML1-ETO9a overexpression was related to short event-free and overall survival time (P ¼ 0.0072 and P ¼ 0.0076, respectively). Taken together, these data suggest that AML1-ETO9a is correlated with C-KIT overexpression/mutations and indicates poor disease outcome in t(8;21) AML-M2.
Introduction
Chromosomal translocation, t(8;21)(q22;q22), which generates AML1-ETO fusion gene, represents one of the most common cytogenetic abnormalities in acute myeloid leukemia (AML). 1 It is observed in 15-40% of AML-M2 subtype according to the French-American-British classification, 2 which is characterized by specific morphologic features, such as aberrant myelocytes. 3, 4 However, the AML1-ETO knockin and transgenic mice fail to develop leukemia, 5 suggesting that additional aberrations might be involved. 6 Recently, it has been reported that an alternatively spliced isoform of AML1-ETO, AML1-ETO9a, encoding a C-terminally truncated AML1-ETO protein, can rapidly induce leukemia in a mouse retroviral transductiontransplantation model. Coexpression of AML1-ETO and AML1-ETO9a results in the substantially earlier onset of AML and blocks myeloid cell differentiation at a more immature stage. 7 However, the clinical significance of AML1-ETO9a expression remains to be investigated.
The C-KIT proto-oncogene encodes a class III transmembrane receptor tyrosine kinase and plays an important role in tumor development, including hematopoietic malignancies. 8 C-KIT overexpression and/or mutations have been identified in t(8;21) AML 9, 10 and referred to poor disease outcome of these patients. 11, 12 Our earlier study suggested that AML1-ETOpositive AML follow a stepwise model in leukemogenesis, in which activating C-KIT may be a secondary but crucial hit for the development of full-blown leukemia. 13 In this report, we further described a close correlation of AML1-ETO9a with C-KIT, as well as related clinical and prognostic significance in 118 patients with t(8;21) AML-M2.
Materials and methods

Patients
From January 1994 to December 2008, a total of 118 patients were diagnosed as t(8;21) AML according to the World Health Organization classification, and treated in the Shanghai Institute of Hematology-based network. The median observation time was 14 months (range from 1 to 128 months). All patients were of M2 subtype according to the French-American-British classification, including 53 pediatric cases (p18 years, median 12 years) and 65 adult cases (418 years, median 41 years). Of all patients, 44 patients, including 21 patients with C-KIT mutations, were earlier reported by Wang et al. 13 The main characteristics of the patients are listed in Table 1 . According to the treatment protocols, these patients could be divided into two groups: (1) standard-dose cytarabine (Ara-C)-based regimen, in which the patients were treated with daunorubicin at a daily dose of 40-60 mg/m 2 for 3 days and Ara-C at 100-150 mg/m 2 per day for 7 days for induction therapy, followed by daunorubicin or mitoxantrone and Ara-C for consolidation. (2) median-dose Ara-C-based regimen, in which the patients were treated with daunorubicin at a daily dose of 40-60 mg/m 2 for 3 days and Ara-C at 100-150 mg/m 2 daily or every 12 h for 7 days for induction therapy, followed by post-remission therapy containing three cycles of median-dose Ara-C 0.5-2 g/m 2 every 12 h on days 1, 3 and 5 every 3-4 weeks. Informed consent was obtained from all patients for this study, in accordance with the regulation of the Shanghai Jiao Tong University School of Medicine Institutional Review Boards in agreement with the 'Declaration of Helsinki'.
RNA extraction and reverse transcriptase (RT)-PCR analysis
For each patient, bone marrow sample was collected at diagnosis and mononuclear cells were enriched by densitygradient centrifugation with Ficoll solution. Total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). First-strand cDNA was synthesized from total RNA using Superscript II reverse transcriptase (Invitrogen) according to the manufacturer's instructions. AML1-ETO9a expression was assessed by the qualitative and nested quantitative RT-PCR, according to Yan M et al. with modifications. 7 To determine the cut-off value between the high and low expressing groups, both qualitative and nested quantitative RT-PCR (Supplementary Figure 1) were carried out on a gradient dilution (10 0 , 10 À1 , 10 À2 , 10
À3
, 10 À4 , 10 À5 and 10 À6 dilution) of cDNAs reversetranscribed from 25 ng RNA of Kasumi-1 cells that overexpress AML1-ETO9a. All assays were set up in triplicates. Of note, the qualitative RT-PCR became negative below 10 À3 dilution, equal to AML1-ETO9a expression at the level of 25 pg RNA of Kasumi cells. And in all the patients investigated, the qualitative RT-PCR showed positive results when the quantitative RT-PCR showed relative AML1-ETO9a expression above 10 À3 , and negative results when the quantitative method showed relative AML1-ETO9a expression below 10
. On the basis of these facts, we considered the 10 À3 dilution as the cut-off value. C-KIT expression was assessed as described earlier. 13 For quantitative RT-PCR, the CT method (2 À(CT of gene -CT of internal control) ) was applied to quantify relative gene expression and calibrated by expression levels in positive control cell line Kasumi-1 cells.
GAPDH and b-actin were used as the internal controls for AML1-ETO9a and C-KIT, respectively. Irrelevant cDNA as negative control was included in every step of the assays. PCR products of appropriate size were identified on agarose gels for all the analyzed samples.
Mutation detection for C-KIT, FLT3, JAK2 and N-RAS
To detect C-KIT mutations, all coding regions were amplified by PCR with specific primers according to our earlier report, 13 and the resultant products were sequenced on ABI Prism 3700 DNA Analyzer (Applied Biosystems, Foster City, CA, USA). For FLT3 gene, FLT3-ITD was amplified by PCR as described earlier, 14 and abnormal longer PCR products were identified on agarose gels. FLT3-D835 mutation was detected by RT-PCR using specific primers (forward primer of 5 0 -TGTCACCCACGGGAAAGTG-3 0 and reverse primer of 5 0 -GATGGCCGTTTCCTTGAGTC-3 0 ) and direct sequencing. Detection of JAK2-V617F mutation was carried out by MassArray assay according to our earlier report.
15 N-RAS mutations including codons 12, 13 and 61 were detected by direct sequencing of PCR products as described by Shih et al. 16 
Morphology
Cell morphology was studied on the bone marrow and peripheral blood smear using Wright-Gimesa's staining for each patient at diagnosis. Cytochemically, peroxidase (POX), 
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specific esterase (CE) and non-specific esterase (AE) tests were performed.
Immunophenotyping MPO, HLA-DR, CD13, CD33, CD34, CD19, CD56 and CD117 were examined using immunohistochemistry (Dako, Glostrup, Denmark) for patients diagnosed before 2001, and using flow cytometry analysis (BD, Franklin Lakes, NJ, USA) for those diagnosed after 2001. MPO and CD117 were referred to positive when their expression rates were X10%. 17, 18 The remaining membrane antigens were referred to positive when the expression rates were X20%.
Karyotyping
The R-and G-Banded karyotype was prepared and analyzed according to the International System for Human Cytogenetic Nomenclature (2005). 19 
Statistical analysis
Statistical results were represented as the mean ± s.e. Differences in clinical characteristics of two patient groups were analyzed with the Mann-Whitney test for continuous variables and w 2 -test or Fisher's exact test for binary variables. Complete remission, relapse, relapse-free survival, event-free survival (EFS) and overall survival (OS) were measured according to the criteria recommended by the International Working Group. 20 Survival analyses were estimated using the KaplanMeier method and compared by the log-rank test. Multivariate survival analysis was carried out using a Cox regression model. P values were two-tailed and o 0.05 was considered statistically significant. Statistical analysis was carried out using SPSS 13.0 (SPSS Inc., Chicago, IL, USA).
Results
AML1-ETO9a in close correlation with C-KIT overexpression/mutation in patients with t(8;21) AML-M2
By qualitative RT-PCR, AML1-ETO9a was detected in 86 (72.9%) of 118 patients with t(8;21) AML-M2. Furthermore, using nested quantitative RT-PCR, all these cases expressed high-level AML1-ETO9a (0.34±0.06) and were referred to as the AML1-ETO9a-H group. The remaining 32 patients had a much lower AML1-ETO9a expression (4.91 Â 10 À5 ±1.78 Â 10
À5
, Po0.0001, Figure 1a) , which was detectable with the quantitative method. These cases were referred to as the AML1-ETO9a-L group. The 10 À3 of relative AML1-ETO9a expression was defined as the cut-off value (the detailed description in section of Materials and methods).
It is interesting that, significantly increased C-KIT mRNA levels were observed in the AML1-ETO9a-H group, as compared with the AML1-ETO9a-L group (0.31±0.05 vs 0.05± 0.02, Po0.0001, Figure 1b) . On the other hand, of the 115 investigated patients, 36 presented C-KIT mutations (Table 2) . A total of 32 out of these 36 cases belonged to AML1-ETO-9a-H group (32/86, 37.2%), whereas only four mutations were observed in AML1-ETO9a-L group (4/29, 13.8%, P ¼ 0.0209, Table 2 ). Notably, two novel C-KIT mutations were discovered, being located in transmembrane and juxtamembrane domain, respectively ( Table 2 , supplementary Figure 2a and 2b) . Meanwhile, other important protein tyrosine kinase family members and signaling molecules, such as FLT3, JAK2 and N-RAS, were also screened for mutations. In the AML1-ETO-9a-H group, one patient had a FLT3-ITD mutation, whereas another had a JAK2-V617F mutation (Table 2 ). Neither FLT3-D835 nor N-RAS mutation was detected.
Distinct clinical features according to AML1-ETO9a expression levels in patients with t(8;21) AML-M2
According to clinical parameters, higher white blood cells (WBCs) count was found in AML1-ETO9a-H patients (16.64 ± 1.67 Â 10 9 /L) than in AML1-ETO9a-L cases (11.33 ± 1.97 Â 10 9 /L) (P ¼ 0.0451). No statistical difference was observed between the two groups with respect to age, gender, peripheral hemoglobin level and platelet counts ( Table 1) .
One of the morphological features of t(8;21) AML-M2 is the presence of 'aberrant myelocytes', defined as myelocyte-like elements with marked unsynchronization of development of nucleus and cytoplasm, with some nucleoli in the relatively condensed nucleus and a rich cytoplasm presenting some neutrophilic granules as well as vacuoles. These abnormal elements with some degree of differentiation were more frequently observed in AML1-ETO9a-L patients than in AML1-ETO9a-H cases (20.60 ± 2.80% vs 15.06 ± 1.27%, mean ± s.e, P ¼ 0.0479, Table 1 ). Leukemia cells in the AML1-ETO9a-H group showed more primitive blastic characteristics, such as round-oval nucleus with fine delicate chromatins and clearly visible nucleoli, a high nuclear/cytoplasmic ratio and a cytoplasm with azurophilic staining (Figure 2a) , whereas most of the AML1-ETO9a-L cases presented more aberrant myelocytes (Figure 2b ). Immunophenotype analysis indicated that CD19 and CD56 were expressed in 34/75 (45.3%) and 34/55 (61.8%) cases of the AML1-ETO9a-H group, in contrast to 16/22 
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B Jiao (72.7%) and 3/13 (23.1%) cases, respectively, in the AML1-ETO9a-L group (P ¼ 0.0298 and P ¼ 0.0149, respectively) ( Table 1) . Consistent with C-KIT mRNA level, higher expression of CD117 were present on the AML1-ETO9a-H leukemia cells than that on the AML1-ETO9a-L ones (67.78±4.76% vs 37.28 ± 6.65%, P ¼ 0.0015, supplementary Table 1 ). Cytogenetically, no significant difference was found in terms of loss of sex chromosome between the two groups (P ¼ 0.8360, Table 1 ).
AML1-ETO9a-H as an indicator of poor disease outcome in t(8;21) AML-M2
Of the 118 patients, AML1-ETO9a-H group tended to have a lower complete remission rate than the AML1-ETO9a-L group, although the difference did not reach to statistical significance (77.9 vs 93.8%, P ¼ 0.0578). No significant difference of average relapse rate was observed between two groups (71.6 vs 60.0%, P ¼ 0.3462) ( Table 1 ). An apparent, though not yet statistically significant, negative effect was observed on 2-year relapse-free survival (RFS) (n ¼ 97): RFS rate being 21.07%( ± 5.80%) in AML1-ETO9a-H group, whereas 46.98%(±10.34%) in AML1-ETO9a-L group (P ¼ 0.0519). The 2-year EFS and OS rates ( ± s.e. percentage, n ¼ 118) were 23.81 ( ± 4.51%) and 36.18% ( ± 5.34%), respectively, whereas the 5-year EFS and OS rates were 12.60 ( ± 3.74%) and 15.51% ( ± 4.53%), respectively, with medians at 13 months and 18 months, respectively. Poor EFS and OS rates were correlated with AML1-ETO9a expression (Figure 3a and 3b, respectively) , in that the 2-year EFS and OS rates for the AML1-ETO9a-H group were 15.48 ( ± 4.64%) and 27.34% ( ± 5.84%), respec- Previously undescribed type of C-KIT mutation. Figure 2 Distinct leukemia cell morphological features according to AML1-ETO9a expression levels. (a) In the AML1-ETO9a-H patients, leukemia blasts (c, arrow heads) with primitive characteristics showed round-oval nucleus with fine delicate chromatins and clearly visible nucleoli, and a high nuclear/cytoplasmic ratio and a cytoplasm with azurophilic staining. (b) Typical aberrant myelocytes (-, arrows) were found in the AML1-ETO9a-L patients, which are defined as myelocyte-like elements with marked unsynchronization of development of nucleus and cytoplasm, with some nucleoli in the nucleus and a rich cytoplasm presenting some neutrophilic granules as well as vacuoles.
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tively, significantly lower than those in the AML1-ETO9a-L group (44.62 (±9.87%) and 58.65 (±10.40%), P ¼ 0.0072 and P ¼ 0.0076, respectively). When the effect of therapeutic regimens were considered, among patients receiving standard-dose Ara-C-based chemotherapy, both EFS and OS were better in the group of AML1-ETO9a-L than that in the group of AML1-ETO9a-H (P ¼ 0.0128 and P ¼ 0.0068, Figure 4a and 4b, respectively). However, among patients receiving median-dose Ara-C-based chemotherapy, this superiority of EFS and OS correlated with AML1-ETO9a-L tended to disappear (P ¼ 0.1583 and P ¼ 0.3569, Figure 4c and 4d, respectively). Multivariate analysis showed that AML1-ETO9a expression level, and age were the unfavorable predictors for OS, whereas the chemotherapy regimen represented a protective factor in this series (Table 3) . No statistical differences were noted when all the patients were grouped according to gender, adult or pediatric patients, WBCs count, percentage of aberrant myelocytes or C-KIT expression level (Table 3) .
Discussion
Our data from 118 patients with t(8;21) AML-M2 further confirmed, from the clinical point of view, that AML1-ETO9a contributed to leukemia development. It has been shown earlier that, unlike the full-length AML1-ETO, the truncated fusion protein may stimulate cell cycle progression 21, 22 that could explain the elevated WBCs count in AML1-ETO9a-H group. Morphological study also showed that AML1-ETO9a-H cases exhibited stronger blockage of myeloid differentiation ( Figure 2 ). As recently reported by Peterson et al.,
23 AML1-ETO9a may maintain the leukemia stem cell status through certain key molecules like CD44, a major cellular adhesion molecule implicated in myeloid leukemia pathogenesis. Therefore, AML1-ETO9a may be actively involved in the leukemia cell differentiation arrest and even disease progression in patients with t(8;21) AML-M2. However, in this series, some phenotype differences between patients with high and low expression levels of AML1-ETO9a are of borderline statistical significance, indicating the necessity of larger clinical studies to further confirm these results.
Importantly, prognostic analysis showed that AML1-ETO9a is an independent indicator of poor disease outcome and may thus be considered as an adverse prognostic biomarker. Although t(8;21) AML-M2 has a relatively better clinical course as compared with most of the other subtypes of AML, different groups have reported distinct survival outcomes in t(8;21) AML patients, with relatively poor clinical outcome reported by 
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B Jiao several groups from China. [24] [25] [26] However, a most recently published Chinese paper indicated a significant improved prognosis in t(8;21) AML-M2 patients treated with high-dose Ara-C. 27 These discrepancies might be ascribed to differences in treatment regimens, particularly the use of more intensive chemotherapy. [28] [29] [30] In this study, when analyzed according to treatment protocol, the adverse prognostic effect of AML1-ETO9a-H on EFS or OS was present in the standard Ara-C-based group but not in the median dose one, suggesting that the negative effect of AML1-ETO9a could be weakened by increased dose of Ara-C in the chemotherapy protocol. It is thus of great interest to conduct randomized clinical trial to confirm whether AML1-ETO9a could be further overcome by high-dose Ara-C consolidation.
Secondly, questions are raised as to whether AML1-ETO9a as an alternatively spliced mRNA product contributes to leukemogenesis by themselves alone or, instead, by cooperating with other activated signaling molecules, to produce stepwise disease progression. C-KIT mutation is considered as one of the most important subsequent events on the basis of t(8;21). 31 Induced expression of AML1-ETO in U937-A/E cells significantly upregulated transcriptional and protein levels of C-KIT. 13 In this study, AML1-ETO9a is associated with diminished CD19 and increased CD56 expression on leukemic blasts, in accordance with earlier report in t(8;21) AML with C-KIT activating mutations. 32 Furthermore, as compared with the fulllength AML1-ETO, AML1-ETO9a is more closely correlated with C-KIT overexpression at both transcription (as evidenced by RT-PCR analysis) and translation (as confirmed by CD117 assay) levels, which could also contribute to increased WBCs in AML1-ETO9a-overexpressed patients. 33 These findings strongly suggested an inter-relationship between the genetic events of AML1-ETO9a and C-KIT overexpression/mutation in t(8;21) AML. However, the detailed molecular mechanism involved in AML1-ETO9a regulation of C-KIT needs to be clarified.
In conclusion, AML1-ETO9a overexpression might have endued the t(8;21) AML-M2 with less differentiated features and act as a potential inducer of leukemogenesis by cooperating with C-KIT overexpression/mutations. Targeting the AML1-ETO9a isoform as well as the activated C-KIT could be a promising therapeutic strategy in treating t(8;21) AML-M2. Patients with an unknown variable were included in the analysis using a dummy variable indicating missing data.
c Backward stepwise Cox proportional-hazard modeling was used in multivariate analysis of risk factors.
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